Approved Drug May Be Repurposed to Treat Tumors Resulting from NF2-Related Schwannomatosis
Mass General-led phase 2 clinical trial generates promising results for brigatinib as a treatment for the genetic condition, which is characterized by brain and nerve sheath tumors.
Dr. Plotkin is very knowledgeable and professional. I am happy to be in his care.
Dr Plotkin is an excellent provider and did a great job of explaining what symptoms to look out for
They were very nice and demonstrated care and compassion.
Really he didn't examine me at all. Just talk about my condition. Very sad he didn't examine me st all.
Dr. Plotkin is an excellent doctor.
I am very grateful for the wonderful care I continue to receive from Dr. Plotkin. He is so kind and patient with me.
The experience was very good. Thank you.
Dr Plotkin is an amazing provider and an expert in his field.
Listens and explains well
There is not much more I can say. In the many years I have met with Dr. Plotkin and his staff have been wonderful. Thank you to everyone I deal with at MGH.